Vbi Vaccines Inc – Ordinary Shares (NASDAQ:VBIV) had a decrease of 43.6% in short interest. VBIV’s SI was 981,000 shares in March as released by FINRA. Its down 43.6% from 1.74M shares previously. With 296,400 avg volume, 3 days are for Vbi Vaccines Inc – Ordinary Shares (NASDAQ:VBIV)’s short sellers to cover VBIV’s short positions. The SI to Vbi Vaccines Inc – Ordinary Shares’s float is 2.67%. The stock increased 1.61% or $0.03 during the last trading session, reaching $1.89. About 232,753 shares traded. VBI Vaccines Inc. (NASDAQ:VBIV) has declined 48.69% since March 13, 2018 and is downtrending. It has underperformed by 53.06% the S&P500. Some Historical VBIV News: 22/05/2018 – Well Leveraged: VBI Vaccines Outlines Clinical Trial Progress; 01/05/2018 – VBI Vaccines 1Q-End Cash and Cash Equivalents $58.1M; 12/03/2018 – VBI VACCINES – CO WILL CONTINUE TO HAVE “SIGNIFICANT” OPERATIONAL PRESENCE IN OTTAWA, CANADA; 19/04/2018 – VBI VACCINES INC – TOPLINE DATA FROM PROTECT STUDY ARE EXPECTED MID-YEAR 2019; 17/04/2018 – VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients; 25/05/2018 – VBI Vaccines Announces Results of Annual General Meeting; 17/04/2018 – VBI VACCINES: DSMB RECOMMENDS CONTINUATION OF VBI-1901 STUDY; 20/04/2018 – DJ VBI VACCINES INC COM, Inst Holders, 1Q 2018 (VBV); 19/04/2018 – VBI Vaccines Announces Completion of Enrollment in PROTECT Phase 3 Clinical Study for Sci-B-Vac(R) Hepatitis B Vaccine; 17/04/2018 – VBI VACCINES INC – INDEPENDENT DATA AND SAFETY MONITORING BOARD UNANIMOUSLY RECOMMENDS CONTINUATION OF STUDY WITHOUT MODIFICATION
Analysts expect InflaRx N.V. (NASDAQ:IFRX) to report $-0.44 EPS on April, 4.After having $-0.31 EPS previously, InflaRx N.V.’s analysts see 41.94% EPS growth. The stock decreased 3.27% or $1.59 during the last trading session, reaching $47.02. About 283,484 shares traded or 163.55% up from the average. InflaRx N.V. (NASDAQ:IFRX) has risen 39.39% since March 13, 2018 and is uptrending. It has outperformed by 35.02% the S&P500. Some Historical IFRX News: 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 29/03/2018 – InflaRx Full Year 2017 Financial & Operating Results; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 17/05/2018 – INFLARX NV – CASH POSITION APPROXIMATELY US$137 MLN (EUR 115 MLN) AS OF MARCH 31, 2018; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING
VBI Vaccines Inc., a commercial stage biopharmaceutical company, develops vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company has market cap of $184.58 million. It is developing eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines; and Lipid Particle Vaccine technology, a vaccine formulation technology that enables the thermostabilization of vaccines through a proprietary formulation and freeze-drying process. It currently has negative earnings. The firm also offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborn infants.
More notable recent VBI Vaccines Inc. (NASDAQ:VBIV) news were published by: Globenewswire.com which released: “VBI Vaccines Provides Corporate Update, Outlook for 2019, and Year-End 2018 Financial Results – GlobeNewswire” on February 25, 2019, also Seekingalpha.com with their article: “VBI Vaccines readies stock offering; shares down 7% after hours – Seeking Alpha” published on December 12, 2018, Seekingalpha.com published: “VBI Vaccines closes common stock offering – Seeking Alpha” on December 18, 2018. More interesting news about VBI Vaccines Inc. (NASDAQ:VBIV) were released by: Globenewswire.com and their article: “VBI Vaccines Announces Pricing of $37.5 Million Public Offering – GlobeNewswire” published on December 13, 2018 as well as Seekingalpha.com‘s news article titled: “VBI Vaccines takes issue with critical news article – Seeking Alpha” with publication date: September 17, 2018.
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. The company has market cap of $1.21 billion. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.